Loading...
Loading...
ImmunoCellular Therapeutics, Ltd.
("ImmunoCellular") (NYSE MKT:
IMUC) announced that the US Patent and Trademark
Office (USPTO) has issued a key patent covering ImmunoCellular's product
candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting
six tumor antigens that are commonly expressed on glioblastoma. The claims of
US Patent No. 8,871,211, which issued October 28, 2014, include methods of
treating neural cancer by administering a dendritic cell composition
comprising peptide epitopes of the six tumor antigens of ICT-107. The claims
specifically cover administration of the recited dendritic cell composition to
a patient suffering from glioma, which is inclusive of glioblastoma
multiforme.
"This patent provides important protection for ICT-107, and adds to
ImmunoCellular's intellectual property estate for our cancer vaccine
portfolio," said Andrew Gengos, ImmunoCellular Chief Executive Officer.
The ICT-107 patent was issued to Cedars Sinai Medical Center, and is
exclusively licensed to ImmunoCellular Therapeutics.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in